In a study by Chang et al. [235], the dual-action anti-CSF-1R-IL10 fusion protein, known as BF10, exhibited the ability to diminish tumor growth in a syngeneic preclinical model of HNSCC. The gene discussed is IL10; the disease is neoplasm.